SCHEDULE 13G/A: Franklin Resources Reports Zero Beneficial Ownership in Marinus Pharmaceuticals

Franklin Resources, Inc. and its principals, Charles B. Johnson and Rupert H. Johnson, Jr., have filed an amended Schedule 13G indicating they no longer beneficially own any shares of Marinus Pharmaceuticals, Inc. common stock as of December 31, 2024.

Summary

• Franklin Resources, Inc., along with Charles B. Johnson and Rupert H. Johnson, Jr., filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in MARINUS PHARMACEUTICALS, INC.
• As of the event date of December 31, 2024, the reporting persons collectively hold 0.00 shares, representing 0.0% of the common stock class of Marinus Pharmaceuticals, Inc.
• This filing indicates a complete divestment or reduction below the 5% reporting threshold by these entities.
• The filing confirms that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• Franklin Resources, Inc. is identified as a parent holding company, and its Investment Management Subsidiaries' clients have the right to receive dividends and proceeds from the sale of securities.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of ownership change, indicating a complete divestment by a previously reportable holder. While a divestment could be seen negatively, the filing itself is neutral in tone and provides no operational or financial performance details for the issuer.

Negatives

• The filing indicates that Franklin Resources, Inc. and its principals no longer hold a reportable beneficial ownership stake (0.0%) in Marinus Pharmaceuticals, Inc., which could be interpreted as a lack of confidence or a strategic divestment by a significant institutional investor.

Future Outlook

This document does not contain any forward-looking statements or guidance regarding Marinus Pharmaceuticals, Inc.'s future performance or strategic direction. It solely pertains to the beneficial ownership status of the reporting entities.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a standard disclosure of an institutional investor's ownership stake and does not provide specific insights into broader industry trends for the pharmaceutical sector or Marinus Pharmaceuticals' competitive landscape. It reflects a portfolio management decision by Franklin Resources, Inc.

Stakeholder Impact

• Shareholders: The divestment by a significant institutional investor could lead to negative sentiment or increased selling pressure on Marinus Pharmaceuticals' stock, depending on the market's interpretation of the reasons behind the divestment.

Key Dates

Keywords

Marinus Pharmaceuticals, Franklin Resources, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Ownership Disclosure, Divestment